Adagrasib is another KRAS G12C-specific TKI, for which a phase I/II (KRYSTAL-1) trial involving 79 pre-treated NSCLC patients, administered 600 mg adagrasib, twice daily has been completed [49]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.